"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
| Descriptor ID |
D001682
|
| MeSH Number(s) |
G03.787.151 G07.690.725.129
|
| Concept/Terms |
Biological Availability- Biological Availability
- Availability, Biological
- Availabilities, Biological
- Biological Availabilities
- Biologic Availability
- Physiologic Availability
- Availability, Biologic
- Availabilities, Biologic
- Biologic Availabilities
- Bioavailability
- Bioavailabilities
- Availability, Physiologic
- Availabilities, Physiologic
- Physiologic Availabilities
Availability Equivalency- Availability Equivalency
- Availability Equivalencies
- Equivalencies, Availability
- Equivalency, Availability
|
Below are MeSH descriptors whose meaning is more general than "Biological Availability".
Below are MeSH descriptors whose meaning is more specific than "Biological Availability".
This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 2 | 2 |
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Availability" by people in Profiles.
-
Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer. J Control Release. 2022 08; 348:1089-1115.
-
Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study. Environ Sci Pollut Res Int. 2022 Jul; 29(34):51976-51988.
-
Solid self emulsifying drug delivery system: Superior mode for oral delivery of hydrophobic cargos. J Control Release. 2021 09 10; 337:646-660.
-
Cyclodextrin based bone regenerative inclusion complex for resveratrol in postmenopausal osteoporosis. Eur J Pharm Biopharm. 2021 Oct; 167:127-139.
-
Polyphenols against infectious diseases: Controlled release nano-formulations. Eur J Pharm Biopharm. 2021 Apr; 161:66-79.
-
Amorphous systems for delivery of nutraceuticals: challenges opportunities. Crit Rev Food Sci Nutr. 2022; 62(5):1204-1221.
-
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
-
Quality by Design-Based Crystallization of Curcumin Using Liquid Antisolvent Precipitation: Micromeritic, Biopharmaceutical, and Stability Aspects. Assay Drug Dev Technol. 2020 01; 18(1):11-33.
-
Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration. AAPS PharmSciTech. 2019 Jan 02; 20(1):20.
-
Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186.